RT Journal Article
SR Electronic
T1 FDG SUVmax and DWI ADC for predicting the biological aggressiveness of breast cancers
JF Journal of Nuclear Medicine
JO J Nucl Med
FD Society of Nuclear Medicine
SP 1694
OP 1694
VO 50
IS supplement 2
A1 Nakajo, Masatoyo
A1 Kajiya, Yoriko
A1 Tani, Atsushi
A1 Ueno, Masako
A1 Kaneko, Tomoyo
A1 Nakajo, Masayuki
YR 2009
UL http://jnm.snmjournals.org/content/50/supplement_2/1694.abstract
AB 1694 Objectives To evaluate the usefulness of FDG maximum standardized uptake values (SUVmaxs) and apparent diffusion coefficients (ADCs) for predicting the biological aggressiveness of breast cancer before therapy. Methods Thirty three female patients with breast cancers underwent both FDG-PET/CT and 1.5T MRI diffusion-weighted imaging (DWI) before therapy. Both SUVmaxs and ADCs of breast cancers were calculated. The pathological diagnosis consisted of invasive ductal carcinoma (IDC, n=27) and non-invasive ductal carcinoma (NIDC, n=6). The histological grades of IDC were grade 1 (n=3), grade 2 (n=14) and grade 3 (n=10). Both SUVmax and ADC (b =1000) were statistically compared between IDC and NIDC, and among the histological grades in IDC. Results Thirty of 33 cancers were visible on both FDG-PET and DWI. The 3 invisible cancers were all less than 5mm in diameter. In 30 visible cancers, significant differences were observed in the SUVmax between IDC (6.8±5.0) and NIDC (2.6±1.2) (P=0.023) and in ADC (x10-3mm2/s) between IDC (0.91±0.15) and NIDC (1.06±0.15) (P=0.028). The threshold levels of 2.0 for SUVmax and 1.11 for ADC yielded the same diagnostic values for diagnosing IDC; sensitivity 92% (22/24), specificity 67% (4/6), PPV 92% (22/24), NPV 67% (4/6) and accuracy 87%(26/30). There were also significant differences in SUVmax (grade 1:1.4±0.6, grade 2: 5.9±4.1, grade 3: 9.3±5.3, P=0.008) and in ADC (grade 1: 1.10±0.09, grade 2: 0.98±0.10, grade 3: 0.77±0.06, P<0.001) among 3 grades. Conclusions These results suggest that both FDG SUVmax and DWI ADC can predict the biological aggressiveness of breast cancers.